Generex Scientist Makes Presentation at National Influenza Congress
November 24, 2009 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) announced that Dr. Douglas Powell, director of Immunobiology at Antigen Express, Inc., Generex’s wholly-owned immunotherapeutics subsidiary, made a presentation on the company’s H1N1 Swine Flu program at a national symposium on influenza.
The meeting, Influenza Congress USA 2009, was held in Washington, D.C last week. Representatives from key US and international agencies, policy makers, major pharmaceutical companies and biotechnology were in attendance.
Dr. Powell presented on the company’s progress towards development of a synthetic peptide vaccine for the H1N1 Swine Flu virus during the session on “Alternatives to traditional egg-based vaccines.” Antigen Express is employing novel modified peptide vaccines for antigen-specific stimulation of CD4+ T helper cells. As the manufacturing process for these peptide vaccines is entirely synthetic, they can be made faster, in greater quantities and at reduced cost relative to egg-based vaccines. The nature of the peptides used for design of the vaccines is such that mutation of a given virus strain would be less likely to render them inactive, as is the case with traditional vaccines.
Antigen Express also has under development an immunotherapeutic vaccine for patients with HER2+ cancers. That compound is the subject of a Phase II efficacy study in patients with breast cancer, a recently completed Phase I study in patients with prostate cancer and a second Phase I study in patients with either breast or ovarian cancer where it is being used in conjunction with another immunotherapeutic peptide. A Phase I study of peptides suitable for an H5N1 avian influenza or H1N1 swine flu vaccines was also recently completed.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
